# Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

> **NCT00181688** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 35 (—)

## Conditions studied

- Ovarian Cancer
- Peritoneal Carcinoma
- Tubal Carcinoma

## Interventions

- **DRUG:** Iressa (ZD1839)
- **DRUG:** Arimidex (Anastrozole)

## Key facts

- **NCT ID:** NCT00181688
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 35 (—)
- **Last updated:** 2012-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00181688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00181688, "Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00181688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*